Research Articlehepatitis C

Identification of a Class of HCV Inhibitors Directed Against the Nonstructural Protein NS4B

Science Translational Medicine  20 Jan 2010:
Vol. 2, Issue 15, pp. 15ra6
DOI: 10.1126/scitranslmed.3000331

You are currently viewing the abstract.

View Full Text

Log in


Abstract

New classes of drugs are needed to combat hepatitis C virus (HCV), an important worldwide cause of liver disease. We describe an activity of a key domain, an amphipathic helix we termed 4BAH2, within a specific HCV nonstructural protein, NS4B. In addition to its proposed role in viral replication, we validate 4BAH2 as essential for HCV genome replication and identify first-generation small-molecule inhibitors of 4BAH2 that specifically prevent HCV replication within cells. Mechanistic studies reveal that the inhibitors target 4BAH2 function by preventing either 4BAH2 oligomerization or 4BAH2 membrane association. 4BAH2 inhibitors represent an additional class of compounds with potential to effectively treat HCV.

Footnotes

  • * These authors contributed equally to this work.

  • Citation: N.-J. Cho, H. Dvory-Sobol, C. Lee, S.-J. Cho, P. Bryson, M. Masek, M. Elazar, C. W. Frank, J. S. Glenn, Identification of a Class of HCV Inhibitors Directed Against the Nonstructural Protein NS4B. Sci. Transl. Med. 2, 15ra6 (2010).

View Full Text